Hennion & Walsh Asset Management Inc. Has $671,000 Stake in UiPath Inc. (NYSE:PATH)

Hennion & Walsh Asset Management Inc. increased its stake in UiPath Inc. (NYSE:PATH) by 79.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 29,578 shares of the healthcare company’s stock after purchasing an additional 13,114 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in UiPath were worth $671,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC acquired a new position in shares of UiPath during the 4th quarter worth about $25,000. HighMark Wealth Management LLC bought a new stake in shares of UiPath in the fourth quarter valued at approximately $27,000. Cypress Capital Management LLC WY acquired a new stake in shares of UiPath in the fourth quarter worth $29,000. GAMMA Investing LLC bought a new position in UiPath during the fourth quarter worth $36,000. Finally, FNY Investment Advisers LLC acquired a new position in UiPath during the 4th quarter valued at $40,000. Institutional investors own 62.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PATH. Scotiabank dropped their price objective on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 29th. JPMorgan Chase & Co. reduced their price objective on UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research report on Thursday, May 30th. KeyCorp reaffirmed a “sector weight” rating on shares of UiPath in a research report on Thursday, May 30th. Finally, Mizuho decreased their price target on shares of UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 30th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, UiPath currently has an average rating of “Hold” and a consensus price target of $18.06.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.37% of the stock is owned by corporate insiders.

UiPath Price Performance

Shares of PATH opened at $12.97 on Wednesday. The company has a market capitalization of $7.43 billion, a P/E ratio of -81.03 and a beta of 0.86. UiPath Inc. has a one year low of $11.07 and a one year high of $27.87. The business’s 50 day simple moving average is $15.92 and its 200-day simple moving average is $20.58.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Wednesday, May 29th. The healthcare company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $335.11 million for the quarter, compared to analyst estimates of $332.84 million. UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. On average, sell-side analysts anticipate that UiPath Inc. will post -0.2 EPS for the current fiscal year.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.